Efficacy of THN102 (a combination of modafinil and flecainide) on vigilance and cognition during 40-hour total sleep deprivation in healthy subjects: Glial connexins as a therapeutic target
Fabien Sauvet, Mégane Erblang, Danielle Gomez-Merino, Arnaud Rabat, Mathias Guillard, Dominique Dubourdieu, Hervé Lefloch, Catherine Drogou, Pascal Van Beers, Clément Bougard, Cyprien Bourrrilhon, Pierrick Arnal, Werner Rein, Franck Mouthon, Francoise Brunner-Ferber, Damien Leger, Yves Dauvilliers, Mounir Chennaoui, Mathieu Charvériat, Fabien Sauvet, Mégane Erblang, Danielle Gomez-Merino, Arnaud Rabat, Mathias Guillard, Dominique Dubourdieu, Hervé Lefloch, Catherine Drogou, Pascal Van Beers, Clément Bougard, Cyprien Bourrrilhon, Pierrick Arnal, Werner Rein, Franck Mouthon, Francoise Brunner-Ferber, Damien Leger, Yves Dauvilliers, Mounir Chennaoui, Mathieu Charvériat
Abstract
Trial registration: ClinicalTrials.gov NCT03182413.
Keywords: executive function; flecainide; modafinil; psychomotor vigilance task; safety; sleep deprivation; sustained attention; working memory.
Conflict of interest statement
This study has been funded by the Armaments Procurement Agency (Direction Générale de l'Armement, DGA, program RAPID MODEFI, French Ministry of Defense). F.M., W.R. and M.Cha. are full time employees of Theranexus, F.B. is a consultant to Theranexus. D.L. received funding or has been main investigator in studies sponsored by Merck, Vanda, Actelion, Vitalaire and Jazz. Y.D. is consultant for Theranexus, UCB Pharma, JAZZ, Bioprojet, Flamel, NLS‐pharma and Theranexus. Other authors have no competing interests to declare.
Figures
Source: PubMed